About Human Growth Hormone
Human growth hormone, also known as somatotropin, is a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the anterior pituitary, and it is required to attain normal size for children and adolescents. It also has major effects on lipid and carbohydrate metabolism of an individual. The effects of human growth hormone are mainly mediated by IGF-1 and IGF-2. There are two forms of recombinant human growth hormone approved in the market: Somatropin and Somatrem. Somatropin has 191 amino acids and Somatrem contains 192 amino acids. Growth hormone deficiency can occur either due to a damage to the pituitary or the hypothalamus gland, or can also be acquired genetically. Some of the signs of growth hormone deficiency are adiposity, short stature, and hypoglycemia.
TechNavio's analysts forecast the Human Growth Hormone market in the US to grow at a CAGR of 3.86 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Human Growth Hormone market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the various human growth hormone drugs available in the US for the treatment of growth hormone deficiency.
TechNavio's report, the Human Growth Hormone Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Human Growth Hormone market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Human Growth Hormone Market in the US 2015-2019
Technavio recognizes the following companies as the key players in the Human Growth Hormone Market in the US: F. Hoffmann-La Roche Ltd., Merck Serono SA, Novo Nordisk A/S and Pfizer Inc.
Other Prominent Vendors in the market are: Eli Lilly, Ipsen, Novartis and Teva Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “Advances in technology have led to the development of needle-free drug delivery devices. These devices make it easy for patients to self-administer drugs and reduce the incidence of injection site reactions, therefore preventing noncompliance in the patient population.”
According to the report, human growth hormone is administered to patients with various complications such as growth hormone deficiency, Noonan and Turner syndromes, and infants who are born small for their gestational age. High incidence and prevalence of these diseases result in increased demand for human growth hormone
Further, the report states that all of the approved drugs available in the market are biologics. The development process of these biologics is expensive, thereby leading to increased pricing of these drugs. These biologics need to be kept in cold storage to retain their efficacy and avoid local reactions. Therefore, special machinery and care are required to ensure the supply of potent growth hormones.
F. Hoffmann-La Roche , Merck Serono, Novo Nordisk , Pfizer , Eli Lilly, Teva Pharmaceutical, Novartis, Ipsen